BRCA1 M1628T

CI-VAR-00002561Explore in graph →NP_009225.1:p.Met1628ThrNM_007294.4:c.4883T>CClinVar 41828 CIViC 3966 rs4986854

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease1unmapped disease
BRCA1 M1628T	(functional)	Functional	D	Supports Unaltered Function	3	submitted	EID10283 High-throughput functional assays were used to classify BRCA1 missense mutations with unknown effects. A complementation assay was developed using BRCA1-null conditional knockout mouse embryonic stem … (full text at CIViC) PMID 23867111 · Bouwman et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
41828	Benign	reviewed by expert panel	3	Breast-ovarian cancer, familial, susceptibility to, 1; Breast neoplasm; Hereditary cancer-predisposing syndrome; Hereditary breast ovarian cancer syndrome; Malignant tumor of breast; Pancreatic cancer, susceptibility to, 4; Familial cancer of breast; Fanconi anemia, complementation group S; BRCA1-related disorder	germline	33